Print

Genomics Collaborative Announces Appointment Of Key Executive Positions 
10/19/2005 5:09:49 PM

Pioneer in human genetics samples provision and validation brings aboard top industry veterans to lead continued growth

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 28, 2004-- As part of its continuing expansion efforts, Genomics Collaborative, Inc., the leader in providing clinical samples and the application of human genetics to target validation for drug discovery, today announced the appointment of Rick Episcopo as President of the Company, and John Boyce, as Senior Director, Business Development. In addition to the new hires, the Company also announced the transition of Dr. Kevin Krenitsky, longtime Senior Vice President and Medical Director, to Senior Vice President, Business Development, where he will lead new business efforts full-time. From FY 2002 to FY 2003, Dr. Krenitsky was a key contributor for Genomics Collaborative's 53% growth rate in revenue.

Both Episcopo and Boyce join Genomics Collaborative after distinguished and successful tenures at Sequenom, Inc. During this period, Sequenom was acknowledged by Deloitte and Touche's "Technology Fast 50 Program" as the second-fastest growing company in San Diego in terms of revenues.

"We're very pleased to have two senior professionals of Rick's and John's caliber aboard as we come off of a record-breaking year at GCI," said Dr. Michael Pellini, CEO of Genomics Collaborative. "They are both proven, successful leaders in a very challenging market. Even before joining GCI, they already comprised a very capable team. We're looking forward to their continued success, helping to lead our own continued strong growth."

Episcopo served as Executive Vice President of Commercial Operations at Sequenom from July 2000 through June 2003, where he oversaw global sales, marketing and customer support for the company's Genetic Systems Business. Under his leadership, the Genetics Systems Business achieved significant growth in their consumable business between Q1 2002 and Q1 2003. Prior to Sequenom, Episcopo was co-founder of Cosmetic Therapeutics, Inc., the first medically-based retail skin care store providing prescription products and cosmetic care. Episcopo is a graduate of the United States Naval Academy.

Boyce most recently served as Director, United States Sales at Sequenom Inc., where he led the successful expansion of Sequenom's MassARRAY system and consumable business in the United States. Boyce was also responsible for designing and executing a strategic sales and marketing initiative, which paved the path for entry into various key market segments.

Before joining Sequenom, Boyce was a Territory Manager for FMC/BioWhittaker from 1998-2000, following posts as a Development Scientist/Technical Service Engineer and later Product Manager, both for Unisyn Technologies.

About Genomics Collaborative

Genomics Collaborative, Inc. (GCI) is pioneering the application of human genetics to target validation for drug discovery and diagnostics. GCI's drug validation programs combine access to its Global Repository® of human DNA, tissue and serum with insights from its highly specialized team of human geneticists, statisticians and bioinformaticists.

Open access to the specimens within GCI's Global Repository® allows clients to gain insight into a potential target's value in humans at the earliest possible stages of drug discovery and development. The result is rapid prioritization of the most promising targets for clinical development, potentially shaving years from the discovery-to-commercial drug development pipeline.

Leveraging Global Repository®, GCI offers a spectrum of services ranging from fee-for-service access to human tissue, DNA, and serum samples to customized gene expression and candidate gene validation studies. Global Repository® is the world's largest and most comprehensive library of 550,000 human genetic samples and detailed clinical records, collected from 120,000 patients representing important populations worldwide. GCI's samples represent most pharmaceutically relevant disease states, including common and rare cancers, as well as inflammatory, endocrine, and cardiovascular disorders, and more.

GCI has signed more than 100 partnerships and access agreements with over 40 pharmaceuticals and biotechnology companies, including Pfizer, Inc., Novartis AG, Celera Diagnostics, and Johnson & Johnson, Inc.

For more information, contact Kevin Krenitsky, MD at 617-661-2400, or visit www.genomicsinc.com.

Contact:

Company Contact: Genomics Collaborative, Inc. Kevin Krenitsky, MD, 617-661-2400 kkrenitsky@genomicsinc.com or Media Contact: Boston Communications Mario Fante, 617-619-9805 mfante@bcww.com

Source: Genomics Collaborative


//-->